{
  "ticker": "FATE",
  "company_name": "Fate Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT00890500",
      "title": "Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hematologic Malignancies, Allogeneic Stem Cell Transplantation",
      "start_date": "2011-01",
      "completion_date": "2013-10",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT02354443",
      "title": "A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Metabolic Disorders",
      "start_date": "2015-06",
      "completion_date": "2017-02",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT06308978",
      "title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)",
      "start_date": "2024-03-28",
      "completion_date": "2042-09-30",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT04106167",
      "title": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma",
      "start_date": "2019-06-11",
      "completion_date": "2023-08-11",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT05934097",
      "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma",
      "start_date": "2022-12",
      "completion_date": "2039-05",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT05950334",
      "title": "FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Relapsed/Refractory B-Cell Lymphoma",
      "start_date": "2023-11-16",
      "completion_date": "2025-06-30",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT04614636",
      "title": "FT538 in Subjects With Advanced Hematologic Malignancies",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma",
      "start_date": "2020-10-17",
      "completion_date": "2023-08-08",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT04245722",
      "title": "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Lymphoma, B-Cell, Chronic Lymphocytic Leukemia",
      "start_date": "2020-03-19",
      "completion_date": "2023-09-27",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT05182073",
      "title": "FT576 in Subjects With Multiple Myeloma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma, Myeloma",
      "start_date": "2021-11-10",
      "completion_date": "2024-10-18",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    },
    {
      "nct_id": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer",
      "start_date": "2022-05-31",
      "completion_date": "2023-08-11",
      "enrollment": 0,
      "sponsor": "Fate Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 23,
    "by_phase": {
      "PHASE1": 19,
      "": 2,
      "PHASE1, PHASE2": 1,
      "PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 7,
      "TERMINATED": 11,
      "RECRUITING": 3,
      "WITHDRAWN": 1,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 4,
    "completed_trials": 7,
    "conditions": [
      "Acute Myelogenous Leukemia, B-cell Lymphoma",
      "Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma",
      "Advanced Solid Tumor",
      "Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma",
      "Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma",
      "Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)",
      "Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma",
      "HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma",
      "Hematologic Malignancies",
      "Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease",
      "Hematologic Malignancies, Allogeneic Stem Cell Transplantation",
      "Hematological Malignancy",
      "Lymphoma, B-Cell, Chronic Lymphocytic Leukemia",
      "Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia",
      "Metabolic Disorders",
      "Multiple Myeloma, Myeloma",
      "Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer",
      "Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)",
      "Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma",
      "Relapsed/Refractory B-Cell Lymphoma",
      "Solid Tumor, Adult"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:22.114934",
    "search_query": "Fate Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Fate+Therapeutics,+Inc."
  }
}